Valeant Pharmaceuticals Intl Inc. Tries to Downplay the Drug-Pricing Scandal

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been caught up in a drug-pricing scandal. What are the long-term implications for the stock?

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been hit hard by allegations of drug pricing, driving the stock down 40% over the past month. Chief Executive Officer Michael Pearson says the company plans to reduce its reliance on drugs, whose prices have been substantially raised, all the while insisting that his company has not been involved in unfair drug pricing.

“The pharmaceutical industry is being aggressively attacked for past pricing actions–not just Valeant, but all companies,” Pearson said in a conference call following the company’s latest earnings report. “Given the environment, the pricing that pharmaceutical companies will take in will be more modest,” he added, suggesting a maximum 10% increase in the future.

The company said that during the next 12 months it will consider selling or privatizing its neurology and “other” drug categories, in which much of the “mispriced” buying has occurred; it’s a small part of Valeant’s business, according to Pearson.

Evercore ISI analyst Umer Raffat said because the drugs in question represent only about 10% of Valeant’s revenues, his outlook for the company remains unchanged. “If you take out neuro and ‘other’, which they may potentially divest, it actually makes the volume price even lesser to the overall business,” he said in a note to clients. “It’s not a big part of their business, and that’s the most important thing.”

So, why is the stock dropping like a stone? Well, even though the company insists its involvement in the drug-pricing scandal is minimal, the U.S. Attorney’s offices in Massachusetts and New York have issued court orders forcing Valeant to turn over documents tied to the U.S. price hikes of two heart drugs.

In the U.S. prices for Nitropress and Isuprel increased by 212% and 525% after the company acquired the rights to sell them. Despite Pearson’s attempts to soothe the market, investors hate uncertainty, and that’s just what this scandal has produced.

This week CIBC World Markets cut its price target on the U.S. version of the stock to $200 from $275, citing the company’s statement that the price of drugs will moderate.

The scandal overwhelmed Valeant’s mainly positive earnings for the third quarter, which were released on Monday. The company’s net income rose to $2.74 per share in the third quarter, up from $2.11 in the third quarter of 2014. Revenue rose to $2.78 billion, just above estimates of $2.77 billion.

The problem for Valeant is that even if it has cleaned up its act over drug pricing, the story could remain high profile as it wends its way through the U.S. court system. For long-term investors, this could be a buying opportunity. But it comes with risk if the courts ultimately sanction Valeant.

Fool contributor Doug Watt has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

This 6.2% Dividend Stock Brings Investors Money Every Month

This 6.2%-yielding TSX dividend stock recently raised its monthly payout again, backed by rising production, strong cash flow, and promising…

Read more »

dreaming of financial success
Dividend Stocks

Passive Income: Is Enbridge Stock Still a Buy for Its Dividend Yield?

Enbridge’s resilient cash flow profile, solid payout history, and a growing earnings base strengthen its appeal as a high yield…

Read more »

diversification and asset allocation are crucial investing concepts
Dividend Stocks

How Many Enbridge Shares You Need for $1,000 in Dividends

Enbridge pays $3.88 a share. At $68.59, you need 258 shares, about $17,696, to earn $1,000 a year in annual…

Read more »

space ship model takes off
Stocks for Beginners

Max Out Your TFSA Room With 2 Canadian Stocks Poised for Growth

These two Canadian growth stocks have strong fundamentals and promising expansion plans that could help TFSA investors build solid long-term…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

3 AI Stocks Canadians May Like Better Than Nvidia

Nvidia's stock is down 32% amid controversies. Discover the implications for Nvidia and the chip industry amid these concerns.

Read more »

Business success of growth metaverse finance and investment profit graph concept or development analysis progress chart on financial market achievement strategy background with increase hand diagram
Stocks for Beginners

3 Best Growth Stocks in Canada for the Long Haul

These three Canadian growth stocks have strong business fundamentals and promising expansion opportunities that could help long-term investors build wealth.

Read more »

A airplane sits on a runway.
Investing

2 Small-Cap Stocks to Watch Right Now

With solid fundamentals and clear growth prospects, these two small-cap stocks are ideal additions to your portfolio.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, November 17

The TSX could remain volatile at the open today as investors digest Quebecor's proposed Telus takeover and Canadian Natural's Advantage…

Read more »